San Diego, Ca., USA - June 8, 2015, San Diego, Ca., USA - Halozyme Therapeutics, Inc., an oncology biotech company, announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor.
Article continues below
Mr. Ramsay joined Halozyme in 2003 as Chief Financial Officer and served in that capacity until 2009 when he was appointed Vice President, Corporate Development. After spending four years in various commercial and operational roles, Mr. Ramsay was appointed Chief Financial Officer.
Prior to Halozyme, he served in various financial roles including Vice President, Chief Financial Officer of Lathian Systems. Prior to Lathian, he was Vice President, Treasurer of ICN Pharmaceuticals, now called Valeant Pharmaceuticals International, a multinational, specialty pharmaceutical company.
Mr. Ramsay joined Valeant from ARCO, where he spent four years in various financial roles, most recently serving as Manager, Financial Planning & Analysis for the company’s Retail Marketing division.
Prior to ARCO, he served as Vice President, Controller for Security Pacific Asian Bank, a subsidiary of Security Pacific Corporation. He began his career as an Auditor at Deloitte & Touche, where he obtained his CPA license.
Mr. Ramsay received his B.S in Business Administration from the University of California, Berkeley, and his MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania.
Ms. Stelzer will assume CFO duties on June 15 and will work with Mr. Ramsay through a transition period.
Most recently at Shire, Ms. Stelzer served as senior vice president of Finance for R&D, Technical Operations and Business Development, and was previously Division CFO for Regenerative Medicine.
Before Shire, she spent 15 years at Amgen, in senior leadership roles in finance and business development with responsibilities including the U.S., Canada and International Markets, ultimately serving as the company's acting treasurer. ■